阿波利波蛋白E (ApoE) ε4在中风后认知障碍中的作用:一项前性队列研究
Jia-Hung Chen1,2,3, Lung Chan2,3, Chien-Tai Hong2,3
1Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Aging
|May 11, 2025
概括
阿波利波蛋白E (ApoE) ε4基因基因与中风后认知障碍 (PSCI) 风险无关. 传统因素,如年龄和中风严重程度,是PSCI的更重要的预测因素.
科学领域:
- 神经学 神经学
- 遗传学 遗传学是一种遗传学.
- 脑卒中研究 脑卒中研究
背景情况:
- 脂蛋白E (ApoE) ε4是已知的阿尔茨海默病的风险因素之一.
- ApoE ε4与中风后认知障碍 (PSCI) 之间的关联需要进一步调查.
研究的目的:
- 调查ApoE ε4等位基因在PSCI发展中的作用.
- 为了确定与PSCI相关的风险因素,在3个月和12个月后缺血性中风.
主要方法:
- 在缺血性中风7天内对患者 (≥20年) 进行前性队列研究.
- 在3个月和12个月时进行ApoE基因型定型,评估基线特征和认知功能评估 (MoCA,CDR).
- PSCI定义为MoCA得分<26,并对混因素进行统计调整.
主要成果:
- 在中风后3个月或12个月,ApoE ε4等位基因与PSCI风险没有显著关联.
- 年龄,体重指数,教育水平和初始中风严重程度与3个月后的PSCI有关.
- 教育水平和3个月的MoCA得分与12个月的PSCI有关.
结论:
- ApoE ε4等位基因似乎不是PSCI的重要风险因素.
- 传统因素和早期认知状态在预测PSCI方面更为关键.
- 建议对更大的队列和更长的随访进行进一步的研究.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
01:26Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170